ChulaCov19 mRNA vaccine Uses, Dosage, Side Effects and more
The ChulaCov19 vaccine is mRNA-based and was developed in Thailand’s Chulalongkorn University in collaboration with the University of Pennsylvania in the US. Pre-clinical studies in mice and monkeys showed evidence that the vaccine facilitates an impressive generation of neutralizing antibodies. The next phase of this study is for phase I and II clinical trials (NCT04566276) beginning in January 2021.
Trade Name | ChulaCov19 mRNA vaccine |
Generic | ChulaCov19 mRNA vaccine |
Type | |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | January 7, 2025 at 1:49 am |